



European Reference Networks: the WHAT, the WHY and the WHEN

Rare Disease – Denmark: Workshop on European Reference Networks (ERNs)

Matt Bolz-Johnson, EURORDIS

28 February 2020

EURORDIS.ORG

Rare Disease Day 2020

RARE DISEASE DAY®

- 13th edition on 29 February 2020
- Thousands of awareness-raising events held in 100 countries!
- Brings together patients, families, patient organisations, healthcare professionals, industry, institutions & policy-makers worldwide to raise awareness.





The WHY: Characteristics & Profile of RD

- Small patient populations, scattered across large geography
- Critical Mass of 263-446M world-wide (3.5-5.9% preval.)
- 98% population affected by <400 rare diseases
- 2% affected by 6,000 RD

Estimating global point prevalence of rare diseases: analysis of the Ornhanet database

- Lack of visibility and recognition of experts
- Clinical outcomes improve in higher volume clinical teams.
- · Centralisation of care and knowledge leads to increased outcomes, but politically senstive

Low prevalence cases

Limited expertise & evidence

Increased complexity

- Complex multi-system, progressive, disabling & degenerative diseases
- >6000 RD heterogeneous in nature, but share common characteristics
- Limited access to adequate care
- Poor outcomes

Ineffective treatments

- Maintain safe and sustainable services clinical competency and financial viability
- Lack of effective treatments
- **High-cost interventions** and requiring high investment

'Giving existence to people living with a rare disease in health systems - Naming, counting, taking action'. Prof. Ana Rath, Orphanet, Inserm US14, France (NGO Committee RD, 2019' Hentschker, C., Mennicken, R., 2018. The Volume—Outcome Relationship Revisited: Practice Indeed Makes Perfect. Health Serv. Res. 53, 15–34. https://doi.org/10.1111/1475-6773.1269 Morche, J., Mathes, T., Pieper, D., 2016. Relationship between surgeon volume and outcomes: a systematic review of systematic reviews. Syst. Rev. 5, 204. https://doi.org/10.1186/s13643-016



The WHAT: ERN Spearhead EU Expertise



Networks harness the collective knowledge and experience of experts, focusing on a common goal to drive improve access to diagnosis and treatment by enabling expertise, not the patient:

- → Connect expert, anchored into national health systems
- → Creating a critical mass of cases and data
- → Inclusive, not exclusive, multi-professional, not single professional
- → Common language, common platform enabling mobility of expertise
- → Collaborative spirit, trust and sharing with a common goal
- → Drive research and new therapies
- → Increase patient outcomes and survival



Types of ERN Membership

- Full HCP Member: Open to all expert centres that meets the specific criteria for expertise in a specific RD
- Affiliated Partners: Member State with without a Member of a Network may decide to designate healthcare providers with a special link to a given Network.
- Patient Representatives: Open to all patient representatives (EURORDIS members & non-members)

Full Member

HCP Member

- 'Endorsed' by their MS under their legislation
- EC Competency
- Complete a Full Application and independent EC Assessment
- Role explicitly defined in the EC ERN Delegated Acts

Affiliated Partner

National Associate Centre

- MS Competency national designation process
- Clinicians, hospitals, laboratories, ...
- No formal definition
- No defined
 designation process
 in MSs

National Coordination Hub

- MS Competency through a designation process
- Coordination and information role
- No formal definition
- No defined designation process in MSs

ePAG Patient Representatives


All Patient Representatives

- Invited members, not legal members
- EUCERD
 Recommendation
- EURORDIS lead the development of common framework to optimize patient involvement
- Creation of 24 ePAG Groups in 24 ERNs



Paradigm Shift in Healthcare for RD


from MDT to 'Networked Care'




potential new system



The WHEN: 20 Years of creating the opportunity ERNs offer



The FUTURE: WHO Global Collaborative Global **Networks for Rare Diseases**




for Rare Diseases



(connecting 6 WHO Regions)



Shift from Coverage to ERN & NHS Integration



Yr		Total	Coverage
2015-16	Application		
2017	Full Members	900	44%
	Member States in All ERNS	3	12.5%
2019	Affiliated Partners	250	74%
	Member States in All ERNS	10	42%
2020	Full Member Applications	850	>95%
2020	ERN RD Expansion	-	+53 RD



NB: National Coordination Hubs - designated by Malta (Mater Dei Hospital), Luxembourg (Centre Hospitalier du Luxembourg) and Hungary (Semmelweis University).

What are the National Needs ... in Denmark?

- 1. What are Denmark's healthcare needs specific to rare diseases and highly specialised healthcare?
- 2. How can ERNs support and complement the Danish healthcare system:
 - For rare disease patient community ...
 - > For expert teams, primary care practitioners (etc...) ...
 - > For hospital services ...
 - For Regional and National Authorities.



Patient Organisations

- Voice of patient community in ERNs
- Bridge to the RD Community

HCP Member Clinical Leads Active in ERN

- Development of guidelines
- Provide advice on **CPMS**
- Research, etc ...

Support clinician's activities in ERN

Data collection


Hospital Managers

Provide infrastructure

Strategic development

Member States

- **Endorsement of HCP Applications**
- Support HCPs activities in ERNs



- Raise awareness of ERNs
- Sharing of information
- National coordination role
- Dissemination of ERN knowledge, information and activities
- Referral of patients into **ERNs**
- Support adoption of ERN products - guidelines and pathways - within the hospital
- Data monitoring and infrastructure
- Organisation of referral pathways into ERN
- Model of care for RD
- **Development of National** Networks
- Assessment and adoption of ERN guidelines
- HCP Members: "boundary role" needed to be active both within an ERN and locally within their respective national systems.
- New role / function of National Coordinators




National Networks (Rec. 1)



Denmark	
Representative in the ERN Board of Member State	s:
Søren NEERMARK, Danish Health Authority	
Members:	
Aarhus University Hospital	Endo-ERN
	ERN LUNG
	ERN eUROGEN
Cananhagan University Harnital Bircharnitalet	EURACAN Endo-ERN
Copenhagen University Hospital Rigshospitalet	ERN EYE
	ERN LUNG
	ERN eUROGEN
	ERN GUARD-HEART
	MetabERN
	ERN PaedCan
	ERN RARE-LIVER
	ERNICA
Odense University Hospital	ERN Skin
	ERNICA
	VASCERN
Zealand University Hospital	ERN Skin




Referral Pathways (Rec. 2)






ERN Information (Rec. 3)

















Education & Training Webinars

- Raise awareness of ERN and leverage the national benefits of networking
- Dissemination of new information and knowledge
- Identify legal and policy developments needed in implement ERN activities



Care Pathways (Rec. 4)

Top-Down

 Review of ERN care pathways and how they can be implemented nationally, assessing impact on care coordination



Disease specific national care pathways

Bottom-Up

- Service mapping and their alignment with the new Network Care Pathways
- Benchmark national pathways on the needs of patients service improvement within hospitals and between hospitals
- Development of national care pathways disease specific, aligned with the ERN recommended structure.



Member State Support (Rec. 5)



- Denmark (probably) will have 50 Health Care Professionals involved in the ERNs by the end of 2020.
- How can expert teams be supported (financial, resources, administrative) to be active within the ERN as well as within Denmark?
- Good will is not enough and will quickly evaporate and is not a sustainable model
- Expert teams need capacity to act and contribute in a meaningful way
- Support experts to be active at a national level, within Denmark and with the ERNs
- Identify hospital resources and infrastructure that can support their experts within the hospital, nationally and within the ERN(s)
 EURORDIS.ORG

Key Messages



- ERNs are more than the sum of their parts.
- 2. Investment into this opportunity will unlock the potential of networking for the local population needs.
- Leading to improvement in the quality of live and reduce burden on individuals, their families and on the healthcare system.
- 4. Once in a lifetime opportunity for the rare disease community, locally within Denmark.
- 5. Opportunity to drive clinical efficacy, service efficiency and reduce waste.
- 6. Opportunity for multi-sector stakeholders and partners to have a structured interface to collaborate.
- 7. Give this opportunity a real chance of delivering and being successful.
- 8. Now, need to focus on leveraging the benefits of ERNs within each Member State ...



Tak for din opmærksomhed







RARE is many

RARE is strong

RARE is proud!



EURORDIS.ORG

